Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Aaron P. Rapoport"'
Autor:
Joseph A. Fraietta, Edward A. Stadtmauer, Aaron P. Rapoport, Bruce L. Levine, Wei-Ting Hwang, Dan T. Vogl, Adam D. Cohen, Megan M. Davis, Carl H. June, Adam Waxman, Don L. Siegel, Alfred L. Garfall, Michael C. Milone, Ehren K. Dancy, J. Joseph Melenhorst
Publikováno v:
Blood Advances. 3:2812-2815
Key points T cells from patients early in myeloma therapy exhibit better fitness for CAR T manufacturing than those from relapsed/refractory patients. CAR T cells may be more effective if manufactured from patients before onset of relapsed/refractory
Autor:
Gwendolyn K. Binder, Thomas H. Faitg, Karen Chagin, Elliot Norry, Jean-Marc Navenot, Edward A. Stadtmauer, Trupti Trivedi, Karen Dengel, Aaron P. Rapoport, Daniel E. Lowther, Rafael G. Amado, Malini Iyengar, Luca Melchiori, Ashraf Badros, Ruoxi Wang
Publikováno v:
Blood Advances. 3:2022-2034
This study in patients with relapsed, refractory, or high-risk multiple myeloma (MM) evaluated the safety and activity of autologous T cells engineered to express an affinity-enhanced T-cell receptor (TCR) that recognizes a peptide shared by cancer a
Autor:
Ashkan Emadi, Zeba N. Singh, Mehmet H. Kocoglu, Aaron P. Rapoport, Vu H. Duong, Maria R. Baer, Ashraf Badros, Rima Koka, Ying Zou, Noa G. Holtzman
Publikováno v:
Leukemia & Lymphoma. 60:3577-3580
Outcomes and life expectancy for patients with multiple myeloma (MM) have improved substantially over the last two decades with advancements in therapy, including autologous stem cell transplantati...
Autor:
A. Badros, Dianna S. Howard, Barry R. Meisenberg, Donna E. Reece, David H. Vesole, Joanne Filicko-O'Hara, Jasleen K Randhawa, Neal Flomenberg, Parameswaran Hari, Aaron P. Rapoport, Gordon L. Phillips
Publikováno v:
Bone Marrow Transplantation. 54:293-299
The most common preparative regimen for autologous transplantation (ASCT) in myeloma (MM) consists of melphalan 200 mg/m2 (MEL 200). Higher doses of melphalan 220–260 mg/m2, although relatively well tolerated, have not shown significant improvement
Autor:
Ahmet Dogan, Mehmet Hakan Kocoglu, Sunita Philip, Ning Ma, Olga Goloubeva, Elizabeth Hyjek, Cameron Dell, Alexander M. Lesokhin, Aaron P. Rapoport, Emily Lederer, Ashraf Z. Badros, Zeba N. Singh, Todd Milliron
Publikováno v:
Blood. 130:1189-1197
Programmed death 1 (PD-1) receptor and its ligand (PD-L1) facilitate immune evasion in multiple myeloma (MM). We hypothesized that pembrolizumab, PD-1-antibody, can enhance antimyeloma cellular immunity generated by pomalidomide, leading to improved
Autor:
Lina Bisharat, David J. Chung, Kelly A. O’Brien, Peiman Hematti, Robert J. Soiffer, David Avigan, David H. McKenna, Lynne Uhl, Jiaxi Zhu, Michele Herman, Natalie S. Callander, Nancy L. Geller, Yvonne A. Efebera, James W. Young, Courtney Nelson, Jacalyn Rosenblatt, Thinle Chodon, Aaron P. Rapoport, Pallawi Torka, Marcelo C. Pasquini, Binod Dhakal, Hillard M. Lazarus, Nina Shah, Ajay K. Nooka, Juan Wu, Lynn O'Donnell, Edmund K. Waller, Dina Stroopinsky, Brent R. Logan
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S62-S63
BMT CTN 1401 is an academically led randomized study of a personalized cancer vaccine in which the combination of DC/MM fusion vaccine and lenalidomide maintenance after autoHCT is compared with maintenance alone as upfront treatment of MM (NCT#02728
Autor:
Jack Aiello, Elisabet E. Manasanch, David Avigan, Nikhil C. Munshi, Madhav V. Dhodapkar, Ajay K. Nooka, Yi Lin, Aaron P. Rapoport, Nina Shah, Karthik A. Ganapathi, Ivan Borrello, Eric L. Smith, Adam D. Cohen, Lissa Gray, Damian J. Green, Jesus G. Berdeja, Ajai Chari, Ravi Vij, Amrita Krishnan
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 8, iss 2
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for immunotherapy of cancer, vol 8, iss 2
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the
Autor:
Yuehui Wu, Emily Butler, Kristin Blouch, Sunil Pandit, M. Phillip DeYoung, James E. Hoffman, Aisha N. Hasan, Jonathan L. Kaufman, Aaron P. Rapoport, Amit Jain, Taiga Nishihori
Publikováno v:
Blood. 134:3134-3134
Background: Emerging clinical data demonstrate that adoptive cellular therapy has potential to be practice-changing in the management of relapsed/refractory multiple myeloma (MM). NY-ESO-1 TCR T (GSK3377794) are autologous polyclonal T cells transduc
Autor:
Ashraf Badros, Emily Lederer, Aaron P. Rapoport, Todd Milliron, Ning Ma, Amin Benyounes, Rebecca Bosley, Katrina Binion, Mehmet H. Kocoglu, Ameet Patel
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e287
Autor:
Maria R. Baer, Vishal Bhatnagar, Saul Yanovich, Yin Wu, Ashraf Badros, Carolynn Harris, Kathleen Ruehle, Todd Milliron, Edward A. Sausville, Aaron P. Rapoport, Olga Goloubeva
Publikováno v:
Cancer. 121:1064-1070
Background Racial disparity in the incidence of multiple myeloma is well established; however, to the authors' knowledge, little is known regarding the impact of racial differences on disease characteristics, response to therapy, and clinical outcome